We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.6%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MXCT icon
101
MaxCyte
MXCT
$112M
$964K 0.13%
137,958
+7,958
+6% +$54.3K
VSTM icon
102
Verastem
VSTM
$510M
$956K 0.13%
56,502
+3,388
+6% +$58.3K
CABA icon
103
CALL
Cabaletta Bio
CABA
$437M
$912K 0.12%
449,000
+26,000
+6% +$68K
AKBA icon
104
PUT
Akebia Therapeutics
AKBA
$354M
$860K 0.11%
+1,200,000
New +$2.57M
CRVS icon
105
Corvus Pharmaceuticals
CRVS
$1.12B
$837K 0.11%
510,126
+27,516
+6% +$50.4K
ISEE
106
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$825K 0.11%
49,099
+2,580
+6% +$38.1K
TCDA
107
PUT
DELISTED
Tricida, Inc. Common Stock
TCDA
$764K 0.1%
+92,900
New +$841K
BLSA
108
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$762K 0.1%
77,274
+3,485
+5% +$34.3K
HEPA
109
DELISTED
Hepion Pharmaceuticals
HEPA
$751K 0.1%
582
+29
+5% +$32K
PBLA
110
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
$750K 0.1%
15
+1
+7% +$46.1K
QSI icon
111
Quantum-Si Incorporated
QSI
$155M
$736K 0.1%
157,363
+12,957
+9% +$63.1K
NKTR icon
112
CALL
Nektar Therapeutics
NKTR
$2.39B
$722K 0.09%
8,927
-7,740
-46% -$1.15M
IMUX icon
113
PUT
Immunic
IMUX
$190M
$696K 0.09%
+6,150
New +$712K
NXTC icon
114
NextCure
NXTC
$16.8M
$686K 0.09%
11,755
+584
+5% +$36.5K
IFRX icon
115
InflaRx
IFRX
$250M
$639K 0.08%
349,468
+18,420
+6% +$57.4K
PLRX icon
116
Pliant Therapeutics
PLRX
$64.4M
$636K 0.08%
90,805
+4,093
+5% +$41.8K
VTGN icon
117
VistaGen Therapeutics
VTGN
$9.89M
$633K 0.08%
17,040
+1,184
+7% +$51.6K
SLDB icon
118
Solid Biosciences
SLDB
$794M
$625K 0.08%
34,744
– –
ATXS
119
DELISTED
Astria Therapeutics
ATXS
$619K 0.08%
92,223
+4,643
+5% +$27.6K
IRON icon
120
Disc Medicine
IRON
$2.96B
$615K 0.08%
14,770
+735
+5% +$38.5K
QCLS
121
Q/C Technologies Inc
QCLS
$20.5M
$612K 0.08%
44
+3
+7% +$38K
TENX icon
122
Tenax Therapeutics
TENX
$363M
$596K 0.08%
459
+25
+6% +$27.8K
RLMD icon
123
Relmada Therapeutics
RLMD
$557M
$588K 0.08%
21,801
+1,058
+5% +$21.9K
KALV
124
DELISTED
KalVista Pharmaceuticals
KALV
$586K 0.08%
39,730
+3,154
+9% +$45.3K
CYCN icon
125
Cyclerion Therapeutics
CYCN
$14.9M
$585K 0.08%
26,373
+1,242
+5% +$29.9K
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.